Return on Assets (ROA)
since 2012
Calculation
AbbVie Inc., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net earnings attributable to AbbVie Inc.1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 3.17% | = | 100 | × | 4,278) | ÷ | 135,161) |
| Dec 31, 2023 | 3.61% | = | 100 | × | 4,863) | ÷ | 134,711) |
| Dec 31, 2022 | 8.53% | = | 100 | × | 11,836) | ÷ | 138,805) |
| Dec 31, 2021 | 7.88% | = | 100 | × | 11,542) | ÷ | 146,529) |
| Dec 31, 2020 | 3.07% | = | 100 | × | 4,616) | ÷ | 150,565) |
| Dec 31, 2019 | 8.84% | = | 100 | × | 7,882) | ÷ | 89,115) |
| Dec 31, 2018 | 9.58% | = | 100 | × | 5,687) | ÷ | 59,352) |
| Dec 31, 2017 | 7.50% | = | 100 | × | 5,309) | ÷ | 70,786) |
| Dec 31, 2016 | 9.01% | = | 100 | × | 5,953) | ÷ | 66,099) |
| Dec 31, 2015 | 9.70% | = | 100 | × | 5,144) | ÷ | 53,050) |
| Dec 31, 2014 | 6.44% | = | 100 | × | 1,774) | ÷ | 27,547) |
| Dec 31, 2013 | 14.14% | = | 100 | × | 4,128) | ÷ | 29,198) |
| Dec 31, 2012 | 19.53% | = | 100 | × | 5,275) | ÷ | 27,008) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
The analysis of the annual financial data reveals several notable trends in profitability, asset growth, and efficiency over the observed period.
- Net Earnings Attributable
- Net earnings displayed substantial volatility across the years. Initial earnings started strong at 5,275 million US dollars in 2012 but experienced a marked decline to 1,774 million in 2014. A recovery phase followed, peaking at 11,542 million in 2021, the highest within the span, before sharply declining again to 4,278 million by 2024. This fluctuation suggests periods of variable profitability and possible impacts from operational or market factors.
- Total Assets
- There was a general upward trajectory in total assets from 27,008 million US dollars in 2012, reaching a peak of 150,565 million in 2020. Afterwards, assets decreased somewhat but remained significantly elevated compared to the early years, indicating considerable company growth and investment in asset acquisition. The asset base more than quintupled over the period, reflecting expansion or strategic capitalization efforts.
- Return on Assets (ROA)
- ROA illustrated a declining trend from an exceptionally high 19.53% in 2012 to lower single-digit levels in later years, with some fluctuations. After initial strong returns, ROA dropped to as low as 3.07% in 2020, slightly recovering to 8.53% in 2021 before declining again toward 3.17% in 2024. This decrease in ROA, despite asset growth, signals diminishing efficiency in generating profits from the asset base over time.
Overall, the data depicts a company with significant asset expansion but variable and ultimately decreasing profitability efficiency. The sharp fluctuations in net earnings combined with declining ROA indicate challenges in sustaining profit margins despite a larger asset foundation.
Comparison to Competitors
AbbVie Inc., ROA, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 3.17% | 4.45% | -9.66% | 5.03% | 13.45% | 0.81% | 7.81% | 14.62% | 3.76% | 11.69% | 6.51% | -2.38% |
| Dec 31, 2023 | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% | 15.92% |
| Dec 31, 2022 | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% | 18.30% |
| Dec 31, 2021 | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% | 17.44% |
| Dec 31, 2020 | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% | 23.07% |
| Dec 31, 2019 | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% | 14.15% |
| Dec 31, 2018 | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 33.57% |
| Dec 31, 2017 | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% | 7.43% |
| Dec 31, 2016 | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% | -3.87% |
| Dec 31, 2015 | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% | -22.26% |
| Dec 31, 2014 | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% | -31.63% |
| Dec 31, 2013 | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% | -19.19% |
| Dec 31, 2012 | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% | -3.88% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 3.17% | 5.30% |
| Dec 31, 2023 | 3.61% | 7.25% |
| Dec 31, 2022 | 8.53% | 10.67% |
| Dec 31, 2021 | 7.88% | 10.42% |
| Dec 31, 2020 | 3.07% | 5.45% |
| Dec 31, 2019 | 8.84% | 9.02% |
| Dec 31, 2018 | 9.58% | 8.97% |
| Dec 31, 2017 | 7.50% | 5.28% |
| Dec 31, 2016 | 9.01% | 8.61% |
| Dec 31, 2015 | 9.70% | 8.93% |
| Dec 31, 2014 | 6.44% | 9.45% |
| Dec 31, 2013 | 14.14% | 9.46% |
| Dec 31, 2012 | 19.53% | 8.30% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc., ROA, long-term trends, comparison to industry (health care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 3.17% | 5.73% |
| Dec 31, 2023 | 3.61% | 7.19% |
| Dec 31, 2022 | 8.53% | 9.66% |
| Dec 31, 2021 | 7.88% | 9.46% |
| Dec 31, 2020 | 3.07% | 5.81% |
| Dec 31, 2019 | 8.84% | 8.32% |
| Dec 31, 2018 | 9.58% | 7.90% |
| Dec 31, 2017 | 7.50% | 5.19% |
| Dec 31, 2016 | 9.01% | 7.31% |
| Dec 31, 2015 | 9.70% | 7.71% |
| Dec 31, 2014 | 6.44% | 8.59% |
| Dec 31, 2013 | 14.14% | 8.76% |
| Dec 31, 2012 | 19.53% | 8.09% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).